Abstract 4551: Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index
John Engelhardt(Bristol-Myers Squibb (United States)), Karen Price(Purchase College), Bryan Irving(Gene Therapy Laboratory), Kimberly Tipton(CytomX Therapeutics (United States)), James W. West(CytomX Therapeutics (United States)), Todd Bunch(The Bristol-Myers Squibb Children's Hospital), Paula So(Bristol-Myers Squibb (United States)), John T. Loffredo(Bristol-Myers Squibb (United States)), Rahima Akter(Bristol-Myers Squibb (United States)), Natalie Bezman(University of California, San Francisco), Wendy Freebern(Bristol-Myers Squibb (Germany))
Cited by 6
Related Papers
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
|Nature Immunology|2008|1.5k
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
|Cancer Cell|2014|1.1k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183